Study of MK-6552 in Participants With Narcolepsy Type 1 (MK-6552-004)

Narcolepsy Clinical Trial

Official title:

A Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Sleep Latency Effects of MK-6552 in Participants With Narcolepsy Type 1

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06179407
• Other study ID #: 6552-004
• Secondary ID: MK-6554-004
• Status: Recruiting
• Phase: Phase 1
• Start date: January 24, 2024
• Est. completion date: December 5, 2024

Study information

• Verified date: April 2024
• Source: Merck Sharp & Dohme LLC
• Contact: Toll Free Number
• Phone: 1-888-577-8839
• Email: Trialsites[@]merck.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of MK-6552 in participants with Narcolepsy Type 1 (NT1). Part 1 will evaluate safety, tolerability, and PK of MK-6552 after administration of ascending doses in a single day to support a dose level decision for Part 2. Part 2 will investigate the PD of MK-6552 after single-day and multiple-day administration. Participants who complete Part 1 and demonstrate that they are able to tolerate at least one dose level of MK-6552 will participate in Part 2.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 12
• Est. completion date: December 5, 2024
• Est. primary completion date: December 5, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Has a diagnosis of NT1, including a valid polysomnography within the previous 5 years and a current diagnosis of NT1 for at least 6 months based on criteria established by the International Classification of Sleep Disorders- Third Edition, or Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) [American Psychiatric Association 2013]
• Is positive for HLA-DQB1*06:02 allele supporting a diagnosis of NT1
• Has a baseline history of unequivocal cataplexy prior to initiation of anti-cataplexy medications
• Reports a total sleep time of > 6 hours on at least 4 out of 7 nights each week within the 4 weeks prior to screening visit

Exclusion Criteria:

• Has history of or current hypertension
• Has underlying cardiovascular or cerebrovascular conditions in which an acute rise in blood pressure would pose a clinical concern, including but nor limited to aneurysms or arteriovenous malformations
• Has a history of renal or hepatic impairment
• Has a history of cardiac ischemia or cerebral ischemia including but not limited to history of stroke, transient ischemic attack, or transient global amnesia
• Based on clinical interview and responses on the Columbia-Suicide Severity Rating Scale, is at imminent risk of self-harm or of harm to others in the opinion of the investigator
• Mentally or legally incapacitated, has significant emotional problems at the time of prestudy (screening) visit or expected during the conduct of the study or has a history of clinically significant psychiatric disorder of the last 5 years
• History of cancer (malignancy)
• Has a history of any of the following sleep disorders: obstructive sleep apnea (OSA) defined as an Apnea Hypopnea Index > 15 per hour per the American Academy of Sleep Medicine alternate criteria, primary insomnia (within the past 6 months), circadian rhythm sleep disorder, shift work sleep disorder (within the past 6 months), clinically significant parasomnia at the discretion of the investigator
• Has a history of seizure disorder, clinically significant head trauma, or past invasive intracranial surgery or clinically significant dementia
• Positive test(s) for Hepatitis B surface antigen, hepatitis C antibodies, or human immunodeficiency virus

Related Conditions & MeSH terms

• Narcolepsy

Intervention

Drug:
• MK-6552
Oral capsule administered according to allocation (Part 1)/randomization (Part 2).
• Placebo
In Part 2, participants will receive multiple days of placebo dosing (7 consecutive days).

Locations

Country	Name	City	State
United States	NeuroTrials Research Inc ( Site 0006)	Atlanta	Georgia
United States	Teradan Clinical Trials, LLC ( Site 0005)	Brandon	Florida
United States	Delta Waves, Inc. ( Site 0008)	Colorado Springs	Colorado
United States	Bogan Sleep Consultants ( Site 0001)	Columbia	South Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Merck Sharp & Dohme LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants experiencing an Adverse Event (AE)	An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants that experience an AE will be reported.	Up to approximately 7 weeks
Primary	Number of participants discontinuing study intervention due to an Adverse Event (AE)	An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants that discontinue study intervention due to an AE will be reported.	Up to approximately 5 weeks
Primary	Sleep Onset Latency Measured by the Maintenance of Wakefulness Test (MWT)	The MWT is a daytime polysomnographic procedure that measures objectively the ability to remain awake during sleep-inducing circumstances. Sleep onset latency is defined as the first occurrence of sustained sleep (i.e. 3 consecutive 30 second epochs of N1 [stage 1] sleep or any single 30 second epoch of N2 [stage 2], N3 [stage 3 and 4 combined] or REM). The primary outcome measure of sleep onset latency measured by the MWT on Day 7 will be reported.	1 hour after each dose on Day 7
Secondary	Area Under the Plasma Concentration-Time Curve of MK-6552 from Time Zero to infinity (AUC0-inf)	Blood samples will be collected at specified intervals for the determination of AUC0-inf. AUC0-inf is defined as the area under the concentration-time curve of MK-6552 from time zero to infinity and will be reported for participants in Part 1.	Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose 1. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose
Secondary	Area Under the Plasma Concentration-Time Curve of MK-6552 from Time Zero to 24 hours postdose (AUC0-24)	Blood samples will be collected at specified intervals for the determination of AUC0-24. AUC0-24 is defined as the area under the concentration-time curve of MK-6552 from time zero to 24 hours postdose and will be reported for participants in Part 1.	Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose 1. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose
Secondary	Time to Maximum Concentration (Tmax) of MK-6552	Blood samples will be collected at specified intervals for the determination of Tmax. Tmax is defined as the time to the maximum concentration of MK-6552 reached and will be reported for participants in Part 1.	Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose 1. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose
Secondary	Maximum Concentration (Cmax) of MK-6552	Blood samples will be collected at specified intervals for the determination of Cmax. Cmax is defined as the maximum concentration of MK-6552 reached and will be reported for participants in Part 1.	Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose 1. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose
Secondary	Concentration of MK-6522 at 2 Hours Postdose (C2h)	Blood samples will be collected at specified intervals for the determination of C2h. C2h is defined as the concentration of MK-6552 reached at 2 hours postdose and will be reported for participants in Part 1.	Day 1: 2 hours postdose
Secondary	Concentration of MK-6522 at 6 Hours Postdose (C6h)	Blood samples will be collected at specified intervals for the determination of C6h. C6h is defined as the concentration of MK-6552 reached at 6 hours post Dose 1 and will be reported for participants in Part 1.	Day 1: 6 hours post Dose 1
Secondary	Concentration of MK-6522 at 18 Hours Postdose (C18h)	Blood samples will be collected at specified intervals for the determination of C18h. C18h is defined as the concentration of MK-6552 reached at 18 hours post Dose 2 and will be reported for participants in Part 1.	18 hours post Day 1 Dose 2
Secondary	Apparent Oral Clearance (CL/F) of MK-6552	Blood samples will be collected at specified intervals for the determination of CL/F. CL/F is defined as the rate at which MK-6552 is completely removed from plasma and will be reported for participants in Part 1.	Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose 1. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose
Secondary	Apparent Volume of Distribution (Vz/F) of MK-6552	Blood samples will be collected at specified intervals for the determination of Vz/F. Vz/F is defined as the theoretical volume that would be necessary to contain the total amount of administered MK-6522 at the same concentration that it is observed in the blood plasma, and will be reported for participants in Part 1.	Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose 1. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose
Secondary	Apparent Terminal Half-life (t½) of MK-6552	Blood samples will be collected at specified intervals for the determination of t½. t½ is defined as the time required to divide the MK-6552 plasma concentration by two after reaching pseudo-equilibrium, and will be reported for participants in Part 1.	Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose 1. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose

External Links

•   Merck Clinical Trials Information